Oncodesign SA and Ipsen Enter into a Research Collaboration for the Development of New Therapeutic Agents against the LRRK2 Parkinson's disease Target
1/5/2012 6:19:39 AM
DIJON, France & PARIS--(BUSINESS WIRE)--Regulatory News:
Oncodesign, a Drug Discovery company and Oncology pharmacology service provider, and Ipsen (Euronext: IPN, ADR: IPSEY), a global specialty-driven pharmaceutical company, announced today that the two companies have entered into a research collaboration to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas. Oncodesign and Ipsen will leverage their respective expertise to bring innovative therapeutic solutions to Parkinson patients.
comments powered by